Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for information and advice about coronavirus (COVID-19), including information about the COVID-19 vaccine, go to the NHS website. You can also find guidance and support on the GOV.UK website.
Change my preferences I’m OK with analytics cookies
Following the publication of NICE guidance on Cannabis-Based Medicinal Products in November and December 2019, a further letter has been issued to share details of the guidance. It also includes other new resources and reminds those who are in the position of deciding whether to prescribe CBPMs of the current process for prescribing.
Following the Government’s announcement on the 1 November 2018 that it would reschedule reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the rescheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.
Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.
The specialist will discuss with you all the other treatment options first, before considering a cannabis-based product.
Currently, it is only likely to be prescribed for the following conditions:
CBD is a chemical substance found in cannabis that has medical benefits.
How do I get a prescription?
It will not get you high, because it does not contain THC (tetrahydrocannabinol), the chemical in cannabis that makes you high.
After taking medical cannabis, it’s possible to develop any of the following side effects:
The main risks of THC cannabis products are:
CBD and THC can affect how other medicines work. Always discuss possible interactions with a specialist.